The effect of etretinate on fibronectin in psoriatic skin.
The distribution of fibronectin in psoriatic skin was studied in 6 patients during treatment with oral etretinate using indirect immunofluorescence technique. In untreated lesions fibronectin was clearly visualized in the dermo-epidermal junction (DEJ) and in the walls of papillary capillaries, and showed a reticular or fibrillar pattern in the dermis. In the horny layer there was some fluorescence which we regarded largely as unspecific. In all patients a transient accentuation of fibronectin accumulation in DEJ was seen after 3-7 days of treatment. Except for some decrease in the amount and intensity of capillary fluorescence, no other notable changes occurred in the fibronectin distribution during 4 weeks of treatment.
D000328:Adult; D005050:Etretinate / Q000494:pharmacology*; D005260:Female; D005347:Fibroblasts / Q000378:metabolism; D005353:Fibronectins / Q000032:analysis*; D005455:Fluorescent Antibody Technique; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000378:metabolism; D012867:Skin / Q000032:analysis* / Q000187:drug effects; D014212:Tretinoin / Q000031:analogs & derivatives*
D005353:Fibronectins; D014212:Tretinoin; D005050:Etretinate